Making cancer fight itself: The promise of PROTACs
Proteolysis-targeting chimeras, or PROTACs, are a new area of research in medicinal chemistry; they can leverage cancer cells’ own protein degradation machinery to target cancerous proteins.
![portrait of Jianchao Zhang](/getmedia/052c2b01-88ba-4841-bbf2-796198754a08/Jianchao-Zhang-crop_1.jpg)
Jianchao Zhang, a research assistant professor at Southern University of Science and Technology, or SUSTech, has always been interested in the mechanism underlying cancer development, and he became intrigued by PROTACs after learning of their potential while working in Hai Rao’s lab. Zhang and his colleagues recently discovered a PROTAC with the potential to treat chronic myeloid leukemia, a type of blood cancer.
“PROTACs are one of the most promising technologies in the biomedical field today and offer significant advantages in overcoming drug resistance and targeting undruggable targets due to their unique design and mechanism of action,” Zhang said.
In the beginning, Zhang worked primarily on cancer biology and metastasis. In 2020, Rao moved from San Antonio, Texas, to SUSTech in Shenzhen, China, where Zhang joined his lab. Zhang and colleagues began searching for chemists to collaborate with to synthesize their PROTACs. A year later, they found Lijing Fang from the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, whose expertise in synthetic chemistry enabled them to embark on their PROTAC project in 2022.
Zhang’s journey with PROTACs was not straightforward. His team tried to target other cancerous proteins for PROTAC development, including one involved in lung cancer but encountered many obstacles.
“PROTACs are easy to design but hard to predict the outcome,” Zhang said.
After altering their design approach, they successfully developed their PROTAC, Arg-PEG1-Dasa, which can degrade the cancerous protein BCR-ABL in chronic myeloid leukemia.
What’s next for Zhang’s lab? Optimizing chemical structure and protein degradation is a critical part of drug discovery.
“We are interested in exploring the effects on (protein) degradation efficiency and rate by other amino acids,” he said. “Additionally, linker optimization is crucial for PROTACs, and we aim to modify linker types to further enhance this single amino acid PROTAC.”
Zhang and his colleagues are also working on designing PROTACs to target different types of cancer and making their PROTACs smaller to improve cellular uptake.
No FDA-approved PROTACs are yet on the market; however, several have made it to clinical trials.
“Currently, among the known drug targets, only about 20% possess active sites that can be bound by traditional small molecule inhibitors,” Zhang said. “The remaining 80% are considered undruggable or difficult to target with conventional approaches. There is a significant potential that the 80% of undruggable targets could be addressed using PROTAC technology.”
If at first you don’t succeed …
Proteolysis-targeting chimeras, or PROTACs are bifunctional molecules consisting of three structural components: a chemical entity binding to a target protein involved in cancer development (commonly referred to as a “warhead”), a chemical entity that binds to an E3 ligase (protein degrader) and a linker that connects these molecules. Together, these components help degrade cancer-promoting proteins through proximity-induced proteolysis.
PROTACs don’t need to bind to an active site or have high binding affinity to target proteins. This allows for significant flexibility in drug development.
Jianchao Zhang’s PROTAC employs the N-end rule degradation pathway, which determines that a protein’s rate of degradation depends on the identity of the N-terminal amino acid. A family of E3 ubiquitin ligases recognizes basic and hydrophobic amino acids, making them an ideal tag for PROTACs.
Using this rule, Zhang added the amino acid arginine to the FDA-approved chronic myeloid leukemia drug dasatinib with a polyethylene glycol linker. This combination degraded the cancerous protein BCR-ABL in both cells and mice.
Zhang said he was somewhat surprised when his team first observed their PROTAC-inhibiting tumor growth in a mouse model.
“It was not a given that our amino acid–based PROTAC would work,” he said. “In fact, my first set of PROTACs did not work.”
Enjoy reading ASBMB Today?
Become a member to receive the print edition monthly and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in People
People highlights or most popular articles
![The visa voyage](/getattachment/3c24e64f-1d8f-41ac-a081-9b9aead13daa/Immigrant-scientist-thumb-490-x-270-px.jpg?lang=en-US&width=490&height=270&ext=.jpg)
The visa voyage
International scientists fight through red tape and regulations for a chance to train and work in the U.S.
![AAAS names fellows](/getmedia/e8a15fdf-dc92-44c8-af30-cc33f22bfb7a/AAAS-fellows-thumb.jpg?width=480&height=270&ext=.jpg)
AAAS names fellows
Sixteen ASBMB members are among the scientists honored by the American Association for the Advancement of Science.
![The best of both worlds](/getmedia/6f48cc06-0c78-488d-8cb8-3efbd3d9df9d/Warner-thumb.jpg?width=480&height=270&ext=.jpg)
The best of both worlds
Blake Warner is chief of the Salivary Disorders Unit and the Sjögren's disease clinic at the NIH.
![In memoriam: Maxine Singer](/getmedia/32d42ded-d7d7-4503-93f4-e921a4245b0c/Maxine-Singer-thumb.jpg?width=480&height=270&ext=.jpg)
In memoriam: Maxine Singer
She was a revolutionary molecular biologist, National Medal of Science recipient, federal health official and inclusion advocate.
!['Challenging membrane' researcher wins Tabor award](/getmedia/4bc987cc-63e2-4703-a2f2-80de5b9a6fcf/Tabor-award-Kondolf-480x270.jpg?width=480&height=270&ext=.jpg)
'Challenging membrane' researcher wins Tabor award
Hannah Kondolf and her colleagues developed a system that activates gasdermin proteins in an efficient and equivalent manner and showed differences in two gasdermins.
![Gary Felsenfeld (1929–2024)](/getmedia/348cabe3-dd69-415f-8744-557c7aa8a171/Felsenfeld-Gary-480x270.jpg?width=480&height=270&ext=.jpg)
Gary Felsenfeld (1929–2024)
Three colleagues remember a researcher whose work at the NIH revealed the dynamic nature of chromatin and its role in gene expression and epigenetic regulation.